_parp-inhibitors-for-the-treatment-of-ovarian-cancer-gottfried-konecny-md-124-uclamdchat-preview-1.jpg "PARP Inhibitors for the Treatment of Ovarian Cancer - Gottfried Konecny, MD | UCLAMDChat from parp Video Screenshot Preview 1")
Gallery_parp-inhibitors-for-the-treatment-of-ovarian-cancer-gottfried-konecny-md-124-uclamdchat-preview-3.jpg "PARP Inhibitors for the Treatment of Ovarian Cancer - Gottfried Konecny, MD | UCLAMDChat from parp Video Screenshot Preview 3")
Gallery_parp-inhibitors-for-the-treatment-of-ovarian-cancer-gottfried-konecny-md-124-uclamdchat-preview-hqdefault.jpg "PARP Inhibitors for the Treatment of Ovarian Cancer - Gottfried Konecny, MD | UCLAMDChat from parp Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 34 minutes 17 seconds
👁 View: 4.6K times
Play Audio:👁 View: 4.6K times
Description:
UCLA Health
UCLA Health
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_mechanism-of-action-of-parp-inhibitors-and-targeting-dna-damage-response-ddr.webp "Understand the mechanism of action of PARP inhibitors and targeting DNA Damage Response (DDR) in this short video")
⏲ 3 min 10 sec ✓ 25-Jul-2019
_personalizing-advanced-ovarian-cancer-treatment-with-parp-inhibitors-and-novel-approaches.webp "PeerView Oncology")
⏲ 57 minutes 11 seconds 👁 2.5K
_bono-parp-qu-tan-caro-est2024-gus-lucioni.webp "Gustavo Lucioni")
_susana-m-campos-md-mph-on-the-role-of-parp-inhibitors-in-the-treatment-landscape-of-ovarian-cancer.webp "Susana M. Campos, MD, MPH, of Dana-Farber Cancer Institute, discusses recent changes to the NCCN Ovarian Cancer Guidelines and the implications for treatment going forward.")
⏲ 1 min 37 sec ✓ 26-Apr-2018
_parp-inhibitors-revolutionising-cancer-treatment.webp "astrazeneca")
_linda-mileshkin-mbbs-on-solid-tumors-early-treatment-study-results.webp "Linda Mileshkin, MBBS, of the Peter MacCallum Cancer Centre, discusses phase Ib trial findings on the anti–PD-1 monoclonal antibody BGB-A317 in combination with the PARP inhibitor BGB-290 in advanced solid tumors.")
_an-overview-of-parp-inhibitors-in-ovarian-cancer.webp "Targeted Oncology")
_parp-inhibitors-for-ovarian-cancer.webp "VJOncology")
_mechanism-of-action-of-parp-inhibitors-and-targeting-dna-damage-response-ddr.jpg)
_personalizing-advanced-ovarian-cancer-treatment-with-parp-inhibitors-and-novel-approaches.jpg)
_bono-parp-qu-tan-caro-est2024-gus-lucioni.jpg)
_susana-m-campos-md-mph-on-the-role-of-parp-inhibitors-in-the-treatment-landscape-of-ovarian-cancer.jpg)
_parp-inhibitors-revolutionising-cancer-treatment.jpg)
_linda-mileshkin-mbbs-on-solid-tumors-early-treatment-study-results.jpg)
_an-overview-of-parp-inhibitors-in-ovarian-cancer.jpg)
_parp-inhibitors-for-ovarian-cancer.jpg)
![[+]](/images/menu.gif){kind=small}